Eurofins Scientific SE

ERF: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€69.00DfryqyrHcyjljvt

Eurofins Maintains 2022 Guidance and Core Business Supports Growth; Maintaining FVE

Narrow-moat Eurofins reported solid third-quarter results with no change to its 2022 outlook, despite global macroeconomic headwinds and the war in Ukraine. Organic revenue growth and value-added acquisitions compensated for the decline in coronavirus sales year over year. We are maintaining our EUR 80 fair value estimate, and shares remain undervalued at EUR 62.

Sponsor Center